Scott Curley, general manager of Astra Zeneca Hong Kong, discusses how his affiliate managed to achieve its successful product launch track record; shares his insights on the key specificities of Hong Kong and further explains why it is an important market for Astra Zeneca’s global R&D.
Having previously worked extensively in global product strategy roles, how have you adjusted to your new responsibilities since joining AstraZeneca Hong Kong as General Manager in February 2015?
"Hong Kong had initially been seen as a next-tier market because of its size but I quickly realized when I arrived that the public healthcare system – under the Hospital Authority – facilitates speedy regulatory approval of innovative new medicines"
